Cominarty 30.0 _g Concentrate for dispersion for injection
PDF Leaflet Revision Date: 25 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunisation to prevent COVID-19 in individuals 12 years and older.
Dosage (summary)
2 doses of 0.3 mL each, second dose 3 weeks after the first.
Special Populations
- Elderly
- Immunocompromised
Pregnancy & Breastfeeding
Use in pregnancy only if benefits outweigh risks; unknown if excreted in breast milk.
Contraindications
- Hypersensitivity to vaccine components
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Chills
Counselling Points
- Monitor for 15 mins post-vaccination
- Report any severe reactions
- Do not mix with other vaccines
Serious warnings
- Anaphylaxis risk
- Myocarditis and pericarditis risk
- Postpone in acute illness
Important Disclaimer
The Cominarty 30.0 _g Concentrate for dispersion for injection professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
